Abivax shareholders vote on private placement share issue with preemptive rights waived

• Abivax shareholders will vote on May 11, 2026 on a board authorization to issue ordinary shares or equity-linked securities with waiver of pre-emptive subscription rights.
• Mandate would run for 18 months, allowing placements mainly with qualified growth or pharma-focused investors, strategic partners, or financial intermediaries arranging such placements.
• Resolution sets a maximum nominal amount of EUR 750,000 for potential capital increases under this delegation.
• It also authorizes issuance of debt securities up to a maximum nominal amount of EUR 2 billion under the same framework.
• Auditors raised no objections to pricing methodology described by board, supporting passage of resolution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.